This Analyst Just Hiked Their UnitedHealth Stock Price Target by 50%. Should You Buy UNH Now?

Shares of UnitedHealth (UNH) are experiencing a modest rise on Wednesday following an optimistic update from senior Wells Fargo analyst Stephen Baxter regarding the global leader in health insurance.

This morning, Baxter reaffirmed an “Overweight” rating on UNH and elevated his price target to $400, suggesting a potential upside of approximately 8% from current prices.

• The Chart’s Flashing a New Warning: META Stock Could Tumble to $500 From Here

• Trump Just Took a 10% Stake in Trilogy Metals. Should You Buy TMQ Stock Here?

• I Told You How to Trade AMD Stock to $200. Now That It’s an ‘AI Hero,’ Here’s 1 Way to Play Its Next Move.

• Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.

Baxter’s optimistic assessment is noteworthy, especially as UnitedHealth’s stock has already surged by over 50% since the beginning of August.

Just days ago, UnitedHealth revealed plans to reduce its Medicare Advantage offerings, a move that is expected to impact around 180,000 beneficiaries.

Despite this, Baxter encourages investors to consider holding UNH, emphasizing its strong position in employer-sponsored and government insurance, serving over 50 million members worldwide.

The investment firm has adjusted its earnings expectations upwards for the upcoming quarterly report, linking this to the anticipated extension of increased subsidies.

Additionally, UNH’s dividend yield of 2.39% enhances its appeal, particularly for those focused on income.

Wells Fargo’s analyst noted that UNH’s care delivery and analytics division, Optum, is expanding and showing margin resilience, which he characterized as a structural growth driver that can mitigate immediate utilization challenges.

Notably, despite its recent highs, shares of UnitedHealth are currently trading at an appealing valuation below 1x sales.

Investors looking to buy UNH stock may find reassurance in the fact that renowned investor Warren Buffett has recently reported a significant stake in the health insurance leader, reflecting confidence in its long-term growth and stability.

In summary, Baxter asserts that the recent decline in UnitedHealth’s stock, largely due to regulatory scrutiny and climbing medical costs, is overblown, providing a compelling opportunity for long-term shareholders.

Overall, Wall Street analysts maintain a positive outlook on UnitedHealth’s potential to sustain its upward momentum.